Protective function of sclerosing cholangitis on IBD
Bedke T, Stumme F, Tomczak M, Steglich B, Jia R, Bohmann S, Wittek A, Kempski J, Göke E, Böttcher M, Reher D, Franke A, Lennartz M, Clauditz T, Sauter G, Fründt T, Weidemann S, Tiegs G, Schramm C, Gagliani N, Pelczar P, Huber S
GUT. 2024;73(8):1292-1301.

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal ALP level associated with complication-free survival gain?
Corpechot C, Lemoinne S, Soret P, Hansen B, Hirschfield G, Gulamhusein A, Montano-Loza A, Lytvyak E, Pares A, Olivas I, Eaton J, Osman K, Schramm C, Sebode M, Lohse A, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo F, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil A, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer A, Deibel A, Bruns T, Große K, Wetten A, Dyson J, Jones D, Dumortier J, Pageaux G, de Lédinghen V, Chazouillères O, Carrat F
HEPATOLOGY. 2024;79(1):39-48.

Gut Pathobiont-Derived Outer Membrane Vesicles Drive Liver Inflammation and Fibrosis in Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease
Dorner H, Stolzer I, Mattner J, Kaminski S, Leistl S, Edrich L, Schwendner R, Hobauer J, Sebald A, Leikam S, Acera M, Düll M, Lang R, Seidel G, Seitz T, Hellerbrand C, Fuhrmann G, Distler U, Tenzer S, Eichhorn P, Vieth M, Schramm C, Arnold P, Becker C, Weidinger C, Siegmund B, Atreya R, Leppkes M, Naschberger E, Sampaziotis F, Dietrich P, Rauh M, Wirtz S, Kremer A, Neurath M, Günther C
GASTROENTEROLOGY. 2024;167(6):1183-1197.e16.

ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease
Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M, Bamias G, Barreiro-de Acosta M, Braithwaite T, Greuter T, Harwood C, Juillerat P, Lobaton T, Müller-Ladner U, Noor N, Pellino G, Savarino E, Schramm C, Soriano A, Stein J, Uzzan M, van Rheenen P, Vavricka S, Vecchi M, Zuily S, Kucharzik T
J CROHNS COLITIS. 2024;18(1):1-37.

Fatigue is a symptom of clinical importance in patients with Primary Sclerosing Cholangitis (SOMA.LIV)
Hartl J, Buck L, Löwe B, Toussaint A, Schramm C
J HEPATOL. 2024 [Epub ahead of print].

Symptomerleben und Coping-Strategien bei Patient*innen mit Primär Biliärer Cholangitis: eine qualitative Interviewstudie im Rahmen von SOMA.LIV
Hasenbank N, Buck L, Maehder K, Hartl J, Löwe B, Schramm C, Toussaint A
PSYCHOTHER PSYCH MED. 2024 [Epub ahead of print].

Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis
Hussain N, Ma C, Hirschfield G, Walmsley M, Hanford P, Vesterhus M, Kowdley K, Bergquist A, Ponsioen C, Levy C, Assis D, Schramm C, Bowlus C, Trauner M, Aiyegbusi O, Jairath V, Trivedi P
BMJ OPEN. 2024;14(6):e080143.

Patient experiences of interprofessional collaboration and intersectoral communication in rare disease healthcare in Germany - a mixed-methods study
Inhestern L, Otto R, Brandt M, Zybarth D, Oheim R, Schüler H, Mir T, Tsiakas K, Dibaj P, Zschüntzsch J, Okun P, Hegenbart U, Sommerburg O, Schramm C, Weiler-Normann C, Härter M, Bergelt C
ORPHANET J RARE DIS. 2024;19(1):197.

Multi-omics characterization of healthy and PSC human liver - what we knew and what we have learned
Krause J, Schramm C
J HEPATOL. 2024;80(5):681-683.

IFNγ and CTLA-4 Drive Hepatic CD4 T-Cell Tolerance and Protection From Autoimmunity in Mice
Krzikalla D, Laschtowitz A, Leypoldt L, Gottwick C, Averhoff P, Weidemann S, Lohse A, Huber S, Schramm C, Schwinge D, Herkel J, Carambia A
CELL MOL GASTROENTER. 2024;17(1):79-91.

Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis
Lam L, Soret P, Lemoinne S, Hansen B, Hirschfield G, Gulamhusein A, Montano-Loza A, Lytvyak E, Parés A, Olivas I, Londono M, Rodríguez-Tajes S, Eaton J, Osman K, Schramm C, Sebode M, Lohse A, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo F, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil A, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer A, Deibel A, Bruns T, Große K, Wetten A, Dyson J, Jones D, Levy C, Tanaka A, Dumortier J, Pageaux G, de Lédinghen V, Carrat F, Chazouilléres O, Corpechot C
CLIN GASTROENTEROL H. 2024;22(12):2432-2441.e2.

Gender-affirming hormonal therapy induces a gender-concordant fecal metagenome transition in transgender individuals
Liwinski T, Auer M, Schröder J, Pieknik I, Casar C, Schwinge D, Henze L, Stalla G, Lang U, von Klitzing A, Briken P, Hildebrandt T, Desbuleux J, Biedermann S, Holterhus P, Bang C, Schramm C, Fuss J
BMC MED. 2024;22(1):346.

Antimicrobial glycoprotein 2 (GP2) in gallstones, bile fluid and peribiliary glands of patients with primary sclerosing cholangitis
Lopens S, Schierack P, Krause J, Piaszczyński M, Król R, Staroń R, Krupa Ł, Gutkowski K, Kruk B, Grąt M, Krawczyk M, Patkowski W, Glaser F, Rödiger S, Grossmann K, Pająk J, Milkiewicz P, Lammert F, Zieniewicz K, Schramm C, Roggenbuck D, Krawczyk M
CLIN CHIM ACTA. 2024;562:119841.

Recurrence of autoimmune liver diseases after liver transplantation: Review and expert opinion statement
Montano-Loza A, Corpechot C, Burra P, Schramm C, Selzner N, Ronca V, Oo Y
LIVER TRANSPLANT. 2024 [Epub ahead of print].

Prognostic Scores for Ursodeoxycholic Acid-Treated Patients Predict Graft Loss and Mortality in Recurrent Primary Biliary Cholangitis after Liver Transplantation
Montano-Loza A, Lytvyak E, Hirschfield G, Hansen B, Ebadi M, Berney T, Toso C, Magini G, Villamil A, Nevens F, Van den Ende N, Pares A, Ruiz P, Terrabuio D, Trivedi P, Abbas N, Donato M, Yu L, Landis C, Dumortier J, Dyson J, van der Meer A, de Veer R, Pedersen M, Mayo M, Manns M, Taubert R, Theresa K, Belli L, Mazzarelli C, Stirnimann G, Floreani A, Cazzagon N, Russo F, Burra P, Zigmound U, Houri I, Carbone M, Mulinacci G, Fagiuoli S, Pratt D, Bonder A, Schiano T, Haydel B, Lohse A, Schramm C, Rüther D, Casu S, Verhelst X, Beretta-Piccoli B, Robles M, Mason A, Corpechot C
J HEPATOL. 2024;81(4):679-689.

Hirnabszess als Komplikation bei pulmonaler Manifestation einer HHT
Müller M, Weiler-Normann C, Meyer M, Zeitz M, Buescher G
INNERE MED. 2024;65(1):71-75.

Maternal liver-related symptoms during pregnancy in primary sclerosing cholangitis
Nayagam J, Weismüller T, Milkiewicz P, Wronka K, Bik E, Schramm C, Fuessel K, Zhou T, Chang J, Färkkilä M, Carlsson Y, Lundman A, Cazzagon N, Corrà G, Rigopoulou E, Dalekos G, Båve A, Bergquist A, Ben Belkacem K, Marzioni M, Mancinelli M, Verhelst X, Marschall H, Heneghan M, Joshi D
JHEP REP. 2024;6(1):100951.

Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis
Poch T, Bahn J, Casar C, Krause J, Evangelakos I, Gilladi H, Kunzmann L, Laschtowitz A, Iuso N, Schäfer A, Liebig L, Steinmann S, Sebode M, Folseraas T, Engesæter L, Karlsen T, Franke A, Metabolic Sciences, Max Delbrück Centre for Molecular Medicine in the Helmholtz Association C, Schlein C, Galun E, Huber S, Lohse A, Gagliani N, Schwinge D, Schramm C
CELL REP MED. 2024;5(7):101620.

Integrin αVß6 - autoantigen and driver of epithelial remodeling in colon and bile ducts in primary sclerosing cholangitis and inflammatory bowel disease
Roth D, Düll M, Horst L, Lindemann A, Malzer X, Koop K, Zundler S, Vetter M, Jefremow A, Atreya R, Geppert C, Weidemann S, Waldner M, Dietrich P, Günther C, Munoz L, Herrmann M, Scheffold A, Neurath M, Siebler J, Schramm C, Kremer A, Leppkes M
J CROHNS COLITIS. 2024 [Epub ahead of print].

Next-generation phenotyping integrated in a national framework for patients with ultrarare disorders improves genetic diagnostics and yields new molecular findings
Schmidt A, Danyel M, Grundmann K, Brunet T, Klinkhammer H, Hsieh T, Engels H, Peters S, Knaus A, Moosa S, Averdunk L, Boschann F, Sczakiel H, Schwartzmann S, Mensah M, Pantel J, Holtgrewe M, Bösch A, Weiß C, Weinhold N, Suter A, Stoltenburg C, Neugebauer J, Kallinich T, Kaindl A, Holzhauer S, Bührer C, Bufler P, Kornak U, Ott C, Schülke M, Nguyen H, Hoffjan S, Grasemann C, Rothoeft T, Brinkmann F, Matar N, Sivalingam S, Perne C, Mangold E, Kreiss M, Cremer K, Betz R, Mücke M, Grigull L, Klockgether T, Spier I, Heimbach A, Bender T, Brand F, Stieber C, Morawiec A, Karakostas P, Schäfer V, Bernsen S, Weydt P, Castro-Gomez S, Aziz A, Grobe-Einsler M, Kimmich O, Kobeleva X, Önder D, Lesmann H, Kumar S, Tacik P, Basin M, Incardona P, Lee-Kirsch M, Berner R, Schuetz C, Körholz J, Kretschmer T, Di Donato N, Schröck E, Heinen A, Reuner U, Hanßke A, Kaiser F, Manka E, Munteanu M, Kuechler A, Cordula K, Hirtz R, Schlapakow E, Schlein C, Lisfeld J, Kubisch C, Herget T, Hempel M, Weiler-Normann C, Ullrich K, Schramm C, Rudolph C, Rillig F, Groffmann M, Muntau A, Tibelius A, Schwaibold E, Schaaf C, Zawada M, Kaufmann L, Hinderhofer K, Okun P, Kotzaeridou U, Hoffmann G, Choukair D, Bettendorf M, Spielmann M, Ripke A, Pauly M, Münchau A, Lohmann K, Hüning I, Hanker B, Bäumer T, Herzog R, Hellenbroich Y, Westphal D, Strom T, Kovacs R, Riedhammer K, Mayerhanser K, Graf E, Brugger M, Hoefele J, Oexle K, Mirza-Schreiber N, Berutti R, Schatz U, Krenn M, Makowski C, Weigand H, Schröder S, Rohlfs M, Vill K, Hauck F, Borggraefe I, Müller-Felber W, Kurth I, Elbracht M, Knopp C, Begemann M, Kraft F, Lemke J, Hentschel J, Platzer K, Strehlow V, Abou Jamra R, Kehrer M, Demidov G, Beck-Wödl S, Graessner H, Sturm M, Zeltner L, Schöls L, Magg J, Bevot A, Kehrer C, Kaiser N, Turro E, Horn D, Grüters-Kieslich A, Klein C, Mundlos S, Nöthen M, Riess O, Meitinger T, Krude H, Krawitz P, Haack T, Ehmke N, Wagner M
NAT GENET. 2024;56(8):1644-1653.

Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R-LIVER)
Schregel I, Papp M, Sipeki N, Kovats P, Taubert R, Engel B, Campos-Murguia A, Dalekos G, Gatselis N, Zachou K, Milkiewicz P, Janik M, Raszeja-Wyszomirska J, Ytting H, Braun F, Casar C, Sebode M, Lohse A, Schramm C
LIVER INT. 2024;44(10):2687-2699.

Primär biliäre Cholangitis – Response-Kriterien der Erstlinientherapie und Perspektiven der Zweitlinientherapie
Steinmann S, Schramm C
INNERE MED. 2024;65(4):340-346.

A protective effect of inflammatory bowel disease on the severity of sclerosing cholangitis
Stumme F, Steffens N, Steglich B, Mathies F, Nawrocki M, Sabihi M, Soukou-Wargalla S, Göke E, Kempski J, Fründt T, Weidemann S, Schramm C, Gagliani N, Huber S, Bedke T
FRONT IMMUNOL. 2024;15:1307297.

Optimizing thiopurine therapy in autoimmune hepatitis: A multi-center study on monitoring metabolite profiles and co-therapy with allopurinol
Weltzsch J, Bartel C, Waldmann M, Renné T, Schulze S, Terziroli Beretta-Piccoli B, Papp M, Ye O, Ronca V, Sebode M, Lohse A, Schramm C, Hartl J
HEPATOLOGY. 2024;80(5):1026-1040.

A Gradient of Intestinal Inflammation in Primary Sclerosing Cholangitis
Wittek A, Steglich B, Casar C, Seiz O, Huber P, Ehlken H, Reher D, Wende S, Bedke T, Kempski J, Böttcher M, Bang C, Thingholm L, Krech T, Lohse A, Sauter G, Rösch T, Franke A, Schramm C, Gagliani N, Pelczar P, Huber S
INFLAMM BOWEL DIS. 2024;30(6):900-910.

HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells
Zecher B, Ellinghaus D, Schloer S, Niehrs A, Padoan B, Baumdick M, Yuki Y, Martin M, Glow D, Schröder-Schwarz J, Niersch J, Brias S, Müller L, Habermann R, Kretschmer P, Früh T, Dänekas J, Wehmeyer M, Poch T, Sebode M, , Ellinghaus E, Degenhardt F, Körner C, Hoelzemer A, Fehse B, Oldhafer K, Schumacher U, Sauter G, Carrington M, Franke A, Bunders M, Schramm C, Altfeld M
GUT. 2024;73(2):325-337.

Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report
Andrade R, Aithal G, de Boer Y, Liberal R, Gerbes A, Regev A, Terziroli Beretta-Piccoli B, Schramm C, Kleiner D, De Martin E, Kullak-Ublick G, Stirnimann G, Devarbhavi H, Vierling J, Manns M, Sebode M, Londoño M, Avigan M, Robles-Diaz M, García-Cortes M, Atallah E, Heneghan M, Chalasani N, Trivedi P, Hayashi P, Taubert R, Fontana R, Weber S, Oo Y, Zen Y, Licata A, Lucena M, Mieli-Vergani G, Vergani D, Björnsson E
J HEPATOL. 2023;79(3):853-866.

Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC
Awoniyi M, Wang J, Ngo B, Meadows V, Tam J, Viswanathan A, Lai Y, Montgomery S, Farmer M, Kummen M, Thingholm L, Schramm C, Bang C, Franke A, Lu K, Zhou H, Bajaj J, Hylemon P, Ting J, Popov Y, Hov J, Francis H, Sartor R
GUT. 2023;72(4):671-685.

Impact on follow-up strategies in patients with primary sclerosing cholangitis
Bergquist A, Weismüller T, Levy C, Rupp C, Joshi D, Nayagam J, Montano-Loza A, Lytvyak E, Wunsch E, Milkiewicz P, Zenouzi R, Schramm C, Cazzagon N, Floreani A, Liby I, Wiestler M, Wedemeyer H, Zhou T, Strassburg C, Rigopoulou E, Dalekos G, Narasimman M, Verhelst X, Degroote H, Vesterhus M, Kremer A, Bündgens B, Rorsman F, Nilsson E, Jørgensen K, von Seth E, Cornillet Jeannin M, Nyhlin N, Martin H, Kechagias S, Wiencke K, Werner M, Beretta-Piccoli B, Marzioni M, Isoniemi H, Arola J, Wefer A, Söderling J, Färkkilä M, Lenzen H
LIVER INT. 2023;43(1):127-138.

Transition for adolescents with a rare disease: results of a nationwide German project
Grasemann C, Höppner J, Burgard P, Schündeln M, Matar N, Müller G, Krude H, Berner R, Lee-Kirsch M, Hauck F, Wainwright K, Baumgarten S, Atinga J, Bauer J, Manka E, Körholz J, Kiewert C, Heinen A, Kretschmer T, Kurth T, Mittnacht J, Schramm C, Klein C, Graessner H, Hiort O, Muntau A, Grüters A, Hoffmann G, Choukair D
ORPHANET J RARE DIS. 2023;18(1):93.

Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis
Hartl J, Rüther D, Duengelhoef P, Brehm T, Steinmann S, Weltzsch J, Glaser F, Sterneck M, Sebode M, Weiler-Normann C, Lütgehetmann M, Schaub G, Haag F, Schramm C, Schulze Zur Wiesch J, Lohse A
LIVER INT. 2023;43(2):393-400.

Letter to the Editor: Living donor liver transplantation for people with PSC
Heinemann M, Adam R, Karam V, Schramm C
HEPATOLOGY. 2023;77(5):E95-E96.

Right and left liver lobe biopsies by minilaparoscopy reveal clinically significant sampling error in staging and grading of autoimmune hepatitis
Johannes H, Malte W, Alali S, Marcial S, Sören W, Ptashynska A, Christina W, Christoph S, Willhelm L, Till K, Jörg S
LIVER INT. 2023;43(6):1269-1276.

Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma
Lapitz A, Azkargorta M, Milkiewicz P, Olaizola P, Zhuravleva E, Grimsrud M, Schramm C, Arbelaiz A, O'Rourke C, La Casta A, Milkiewicz M, Pastor T, Vesterhus M, Jimenez-Agüero R, Dill M, Lamarca A, Valle J, Macias R, Izquierdo-Sanchez L, Castaño Y, Caballero-Camino F, Riaño I, Krawczyk M, Ibarra C, Bustamante J, Nova-Camacho L, Falcon-Perez J, Elortza F, Perugorria M, Andersen J, Bujanda L, Karlsen T, Folseraas T, Rodrigues P, Banales J
J HEPATOL. 2023;79(1):93-108.

Pathogen detection in RNA-seq data with Pathonoia
Liebhoff A, Menden K, Laschtowitz A, Franke A, Schramm C, Bonn S
BMC BIOINFORMATICS. 2023;24(1):.

A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis
Liwinski T, Hübener S, Henze L, Hübener P, Heinemann M, Tetzlaff M, Hiller M, Jagemann B, Surabattula R, Leeming D, Karsdal M, Monguzzi E, Schachschal G, Rösch T, Bang C, Franke A, Lohse A, Schuppan D, Schramm C
ALIMENT PHARM THER. 2023;57(2):224-236.

Understanding illness experiences of patients with primary sclerosing cholangitis: a qualitative analysis within the SOMA.LIV study
Lösken C, Maehder K, Buck L, Hartl J, Löwe B, Schramm C, Toussaint A
BMC GASTROENTEROL. 2023;23(1):.

Psychological distress of adult patients consulting a center for rare and undiagnosed diseases: a cross-sectional study
Mund M, Uhlenbusch N, Rillig F, Weiler-Normann C, Herget T, Kubisch C, Löwe B, Schramm C
ORPHANET J RARE DIS. 2023;18(1):82.

Diagnosis of functional strictures in patients with primary sclerosing cholangitis using hepatobiliary contrast-enhanced MRI: a proof-of-concept study
Poetter-Lang S, Messner A, Bastati N, Ringe K, Ronot M, Venkatesh S, Ambros R, Kristic A, Korajac A, Dovjak G, Zalaudek M, Hodge J, Schramm C, Halilbasic E, Trauner M, Ba-Ssalamah A
EUR RADIOL. 2023;33(12):9022-9037.

DeePSC: A Deep Learning Model for Automated Diagnosis of Primary Sclerosing Cholangitis at Two-dimensional MR Cholangiopancreatography
Ragab H, Westhaeusser F, Ernst A, Yamamura J, Fuhlert P, Zimmermann M, Sauerbeck J, Shenas F, Özden C, Weidmann A, Adam G, Bonn S, Schramm C
RADIOL-ARTIF INTELL. 2023;5(3):e220160.

Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A Multicenter, Retrospective Study
Schregel I, Ramos G, Ioannou S, Culver E, Fa Rkkila M, Schramm C
CLIN GASTROENTEROL H. 2023;21(13):3448-3450.e3.

Human γδ T cell Identification from Single-cell RNA Sequencing Datasets by Modular TCR Expression
Song Z, Henze L, Casar C, Schwinge D, Schramm C, Fuss J, Tan L, Prinz I
J LEUKOCYTE BIOL. 2023;114(6):630-638.

Accuracy of controlled attenuation parameter measurement for the detection of steatosis in autoimmune liver diseases
Steinmann S, Hartl J, Weidemann S, Füssel K, Kroll C, Sebode M, Lohse A, Schramm C
JHEP REP. 2023;5(12):100898.

Improving quality of life in patients with rare autoimmune liver diseases by structured peer-delivered support (Q.RARE.LI): study protocol for a transnational effectiveness-implementation hybrid trial
Uhlenbusch N, Bal A, Balogh B, Braun A, Geerts A, Hirschfield G, Janik M, Lohse A, Milkiewicz P, Papp M, Poppe C, Schramm C, Löwe B
BMC PSYCHIATRY. 2023;23(1):193.

Patient-reported quality of care in primary sclerosing cholangitis
Walmsley M, Tornai D, Cazzagon N, Leburgue A, Mrzljak A, Lenzen H, Carbone M, Madaleno J, Lleo A, Junge N, Schramm C, Bergquist A
LIVER INT. 2023;43(8):1654-1662.

Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE-LIVER online survey
Wunsch E, Krause L, Gevers T, Schramm C, Janik M, Krawczyk M, Willemse J, Uhlenbusch N, Löwe B, Lohse A, Milkiewicz P
LIVER INT. 2023;43(2):381-392.

Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease
Zachou K, Azariadis K, Lytvyak E, Snijders R, Takahashi A, Gatselis N, Robles M, Andrade R, Schramm C, Lohse A, Tanaka A, Drenth J, Montano-Loza A, Dalekos G
JHEP REP. 2023;5(8):.

The co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56bright NK cells
Ziegler A, Fittje P, Müller L, Ahrenstorf A, Hagemann K, Hagen S, Hess L, Niehrs A, Poch T, Ravichandran G, Löbl S, Padoan B, Brias S, Hennesen J, Richard M, Richert L, Peine S, Oldhafer K, Fischer L, Schramm C, Martrus G, Bunders M, Altfeld M, Lunemann S
FRONT IMMUNOL. 2023;14:.

Reply to: "The time is ripe for a randomized controlled trial of oral vancomycin in Primary Sclerosing Cholangitis"
Zigmond E, Schramm C
CLIN GASTROENTEROL H. 2023;21(10):2700.

Bile duct colonization with Enterococcus sp. associates with disease progression in Primary Sclerosing Cholangitis
Zigmond E, Zecher B, Bartels A, Ziv-Baran T, Rösch T, Schachschal G, Lohse A, Ehlken H, Schramm C
CLIN GASTROENTEROL H. 2023;21(5):1223-1232.e3.

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis
Corpechot C, Carrat F, Gaouar F, Chau F, Hirschfield G, Gulamhusein A, Montano-Loza A, Lytvyak E, Schramm C, Pares A, Olivas I, Eaton J, Osman K, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo F, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer A, Deibel A, Dumortier J, Bruns T, Große K, Pageaux G, Wetten A, Dyson J, Jones D, Chazouillères O, Hansen B, de Lédinghen V
J HEPATOL. 2022;77(6):1545-1553.

SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease
Duengelhoef P, Hartl J, Rüther D, Steinmann S, Brehm T, Weltzsch J, Glaser F, Schaub G, Sterneck M, Sebode M, Weiler-Normann C, Addo M, Lütgehetmann M, Haag F, Schramm C, Schulze Zur Wiesch J, Lohse A
UNITED EUR GASTROENT. 2022;10(3):319-329.

Survey uncovering variations in the management of primary sclerosing cholangitis across Europe
Eliasson J, Lo B, Scramm C, Chazouilleres O, Folseraas T, Beuers U, Ytting H
JHEP REP. 2022;4(11):.

Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation
Federici S, Kredo-Russo S, Valdés-Mas R, Kviatcovsky D, Weinstock E, Matiuhin Y, Silberberg Y, Atarashi K, Furuichi M, Oka A, Liu B, Fibelman M, Weiner I, Khabra E, Cullin N, Ben-Yishai N, Inbar D, Ben-David H, Nicenboim J, Kowalsman N, Lieb W, Kario E, Cohen T, Geffen Y, Zelcbuch L, Cohen A, Rappo U, Gahali-Sass I, Golembo M, Lev V, Dori-Bachash M, Shapiro H, Moresi C, Cuevas-Sierra A, Mohapatra G, Kern L, Zheng D, Nobs S, Suez J, Stettner N, Harmelin A, Zak N, Puttagunta S, Bassan M, Honda K, Sokol H, Bang C, Franke A, Schramm C, Maharshak N, Sartor R, Sorek R, Elinav E
CELL. 2022;185(16):2879-2898.e24.

Circulating microbiome in patients with portal hypertension
Gedgaudas R, Bajaj J, Skieceviciene J, Varkalaite G, Jurkeviciute G, Gelman S, Valantiene I, Zykus R, Pranculis A, Bang C, Franke A, Schramm C, Kupcinskas J
GUT MICROBES. 2022;14(1):.

Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the European Liver Transplant Registry
Heinemann M, Liwinski T, Adam R, Berenguer M, Mirza D, Malek-Hosseini S, Heneghan M, Lodge P, Pratschke J, Boudjema K, Paul A, Zieniewicz K, Fronek J, Mehrabi A, Acarli K, Tokat Y, Coker A, Yilmaz S, Karam V, Duvoux C, Lohse A, Schramm C
AM J TRANSPLANT. 2022;22(2):626-633.

The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
Karlsen T, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson S, Sangro B, Martin N, Cecchini M, Dirac M, Belloni A, Serra-Burriel M, Ponsioen C, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade H, Sturm E, Marchesini G, Yki-Järvinen H, Byrne C, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova M, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma A, Mendive J, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus J, Ginès P, Buti M, Newsome P, Burra P, Manns M
LANCET. 2022;399(10319):61-116.

The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts
Liwinski T, Heinemann M, Schramm C
SEMIN IMMUNOPATHOL. 2022;44(4):485-507.

Persistent SOMAtic symptoms ACROSS diseases - from risk factors to modification: scientific framework and overarching protocol of the interdisciplinary SOMACROSS research unit (RU 5211)
Löwe B, Andresen V, Van den Bergh O, Huber T, von dem Knesebeck O, Lohse A, Nestoriuc Y, Schneider G, Schneider S, Schramm C, Ständer S, Vettorazzi E, Zapf A, Shedden-Mora M, Toussaint A
BMJ OPEN. 2022;12(1):.

Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation
Montano-Loza A, Ronca V, Ebadi M, Hansen B, Hirschfield G, Elwir S, Alsaed M, Milkiewicz P, Janik M, Marschall H, Burza M, Efe C, Calışkan A, Harputluoglu M, Kabaçam G, Terrabuio D, de Quadros Onofrio F, Selzner N, Bonder A, Parés A, Llovet L, Akyıldız M, Arikan C, Manns M, Taubert R, Weber A, Schiano T, Haydel B, Czubkowski P, Socha P, Ołdak N, Akamatsu N, Tanaka A, Levy C, Martin E, Goel A, Sedki M, Jankowska I, Ikegami T, Rodriguez M, Sterneck M, Weiler-Normann C, Schramm C, Donato M, Lohse A, Andrade R, Patwardhan V, van Hoek B, Biewenga M, Kremer A, Ueda Y, Deneau M, Pedersen M, Mayo M, Floreani A, Burra P, Secchi M, Beretta-Piccoli B, Sciveres M, Maggiore G, Jafri S, Debray D, Girard M, Lacaille F, Lytvyak E, Mason A, Heneghan M, Oo Y
J HEPATOL. 2022;77(1):84-97.

Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis
Müller A, Casar C, Preti M, Krzikalla D, Gottwick C, Averhoff P, Rosenstiel P, Gelderblom M, Altfeld M, Lohse A, Steinmann S, Sebode M, Krause J, Schwinge D, Schramm C, Carambia A, Herkel J
J HEPATOL. 2022;77(6):1532-1544.

Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group
Pape S, Snijders R, Gevers T, Chazouilleres O, Dalekos G, Hirschfield G, Lenzi M, Trauner M, Manns M, Vierling J, Montano-Loza A, Lohse A, Schramm C, Drenth J, Heneghan M
J HEPATOL. 2022;76(4):841-849.

The Interdisciplinary Diagnosis of Rare Diseases
Rillig F, Grüters A, Bäumer T, Hoffmann G, Choukair D, Berner R, Lee-Kirsch M, Mücke M, Grasemann C, Ripke A, Zeltner L, Müller G, Glauch M, Graessner H, Hauck F, Klein C, Nöthen M, Riess O, Mundlos S, Meitinger T, Kurt T, Wainwright K, Schmitt J, Schramm C, Krude H
DTSCH ARZTEBL INT. 2022;119(27-28):469-475.

Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care
Rüther D, Weltzsch J, Schramm C, Sebode M, Lohse A
J HEPATOL. 2022;77(1):250-251.

Tolerance and autoimmunity in the liver
Schramm C, Oo Y, Lohse A
SEMIN IMMUNOPATHOL. 2022;44(4):393-395.

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis
Schramm C, Wedemeyer H, Mason A, Hirschfield G, Levy C, Kowdley K, Milkiewicz P, Janczewska E, Malova E, Sanni J, Koo P, Chen J, Choudhury S, Klickstein L, Badman M, Jones D
JHEP REP. 2022;4(11):.

Autoimmune Lebererkrankungen--ein Update (Teil 2)
Schregel I, Steinmann S, Schramm C
Gastroenterologie up2date. 2022;18(03):245-260.

Autoimmune Lebererkrankungen--ein Update (Teil 1)
Steinmann S, Schregel I, Schramm C
Gastroenterologie up2date. 2022;18(03):225-241.

Increased concentrations of conjugated bile acids are associated with osteoporosis in PSC patients
Stürznickel J, Behler-Janbeck F, Baranowsky A, Schmidt T, Schwinge D, John C, Lohse A, Schramm C, Heeren J, Schinke T, Amling M
SCI REP-UK. 2022;12(1):.

Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis
Taubert R, Engel B, Diestelhorst J, Hupa-Breier K, Behrendt P, Baerlecken N, Sühs K, Janik M, Zachou K, Sebode M, Schramm C, Londoño M, Habes S, Oo Y, Lalanne C, Pape S, Schubert M, Hust M, Dübel S, Thevis M, Jonigk D, Beimdiek J, Buettner F, Drenth J, Muratori L, Adams D, Dyson J, Renand A, Graupera I, Lohse A, Dalekos G, Milkiewicz P, Stangel M, Maasoumy B, Witte T, Wedemeyer H, Manns M, Jaeckel E
HEPATOLOGY. 2022;75(1):13-27.

Factors associated with severity and persistence of fatigue in patients with primary biliary cholangitis: study protocol of a prospective cohort study with a mixed-methods approach (SOMA.LIV)
Toussaint A, Buck L, Hartl J, Löwe B, Schramm C
BMJ OPEN. 2022;12(12):.

Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease
Uellendahl-Werth F, Maj C, Borisov O, Juzenas S, Wacker E, Jørgensen I, Steiert T, Bej S, Krawitz P, Hoffmann P, Schramm C, Wolkenhauer O, Banasik K, Brunak S, Schreiber S, Karlsen T, Degenhardt F, Nöthen M, Franke A, Folseraas T, Ellinghaus D
COMMUN BIOL. 2022;5(1):.

Correction to: Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group
Venkatesh S, L Welle C, H Miller F, Jhaveri K, Ringe K, Eaton J, Bungay H, Arrivé L, Ba-Ssalamah A, Grigoriadis A, Schramm C, Fulcher A
EUR RADIOL. 2022;32(4):2860.

Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group
Venkatesh S, Welle C, Miller F, Jhaveri K, Ringe K, Eaton J, Bungay H, Arrivé L, Ba-Ssalamah A, Grigoriadis A, Schramm C, Fulcher A
EUR RADIOL. 2022;32(2):923-937.

Nanoparticle-mediated targeting of autoantigen peptide to cross-presenting liver sinusoidal endothelial cells protects from CD8 T-cell-driven autoimmune cholangitis
Carambia A, Gottwick C, Schwinge D, Stein S, Digigow R, Şeleci M, Mungalpara D, Heine M, Schuran F, Corban C, Lohse A, Schramm C, Heeren J, Herkel J
IMMUNOLOGY. 2021;162(4):452-463.

Efficacy of a Brief, Peer-Delivered Self-management Intervention for Patients With Rare Chronic Diseases: A Randomized Clinical Trial
Depping M, Uhlenbusch N, Härter M, Schramm C, Löwe B
JAMA PSYCHIAT. 2021;78(6):607-615.

CK-18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission
Derben F, Engel B, Zachou K, Hartl J, Hartleben B, Bantel H, Schramm C, Dalekos G, Manns M, Jaeckel E, Taubert R
LIVER INT. 2021;41(1):123-127.

Risk factors associated with bleeding after prophylactic endoscopic variceal ligation in cirrhosis
Drolz A, Schramm C, Seiz O, Groth S, Vettorazzi E, Horvatits T, Wehmeyer M, Schramm C, Goeser T, Roesch T, Lohse A, Kluwe J
ENDOSCOPY. 2021;53(3):226-234.

Oxysterol 7-α Hydroxylase (CYP7B1) Attenuates Metabolic-Associated Fatty Liver Disease in Mice at Thermoneutrality
Evangelakos I, Schwinge D, Worthmann A, John C, Roeder N, Pertzborn P, Behrens J, Schramm C, Scheja L, Heeren J
CELLS-BASEL. 2021;10(10):2656.

Update of the simplified criteria for autoimmune hepatitis: evaluation of the methodology for immunoserological testing
Galaski J, Weiler-Normann C, Schakat M, Zachou K, Muratori P, Lampalzer S, Haag F, Schramm C, Lenzi M, Dalekos G, Lohse A
J HEPATOL. 2021;74(2):312-320.

The genetic architecture of primary biliary cholangitis
Gerussi A, Carbone M, Corpechot C, Schramm C, Asselta R, Invernizzi P
EUR J MED GENET. 2021;64(9):104292.

Altered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis
Kummen M, Thingholm L, Rühlemann M, Holm K, Hansen S, Moitinho-Silva L, Liwinski T, Zenouzi R, Storm-Larsen C, Midttun Ø, McCann A, Ueland P, Høivik M, Vesterhus M, Trøseid M, Laudes M, Lieb W, Karlsen T, Bang C, Schramm C, Franke A, Hov J
GASTROENTEROLOGY. 2021;160(5):1784-1798.e0.

Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis
Laschtowitz A, Zachou K, Lygoura V, Pape S, Derben F, Jaeckel E, Oller-Moreno S, Weidemann S, Krech T, Piecha F, Schön G, Liebhoff A, Al Tarrah M, Heneghan M, Drenth J, Dalekos G, Taubert R, Lohse A, Schramm C
JHEP REP. 2021;3(4):100321.

SARS-CoV-2 infection in patients with autoimmune hepatitis
Marjot T, Buescher G, Sebode M, Barnes E, Barritt A, Armstrong M, Baldelli L, Kennedy J, Mercer C, Ozga A, Casar C, Schramm C, Moon A, Webb G, Lohse A
J HEPATOL. 2021;74(6):1335-1343.

Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis
Poch T, Krause J, Casar C, Liwinski T, Glau L, Kaufmann M, Ahrenstorf A, Hess L, Ziegler A, Martrus G, Lunemann S, Sebode M, Li J, Schwinge D, Krebs C, Franke A, Friese M, Oldhafer K, Fischer L, Altfeld M, Lohse A, Huber S, Tolosa E, Gagliani N, Schramm C
J HEPATOL. 2021;75(2):414-423.

Failure of thymic deletion and instability of autoreactive Tregs drive autoimmunity in immune-privileged liver
Preti M, Schlott L, Lübbering D, Krzikalla D, Müller A, Schuran F, Poch T, Schakat M, Weidemann S, Lohse A, Weiler-Normann C, Sebode M, Schwinge D, Schramm C, Carambia A, Herkel J
JCI INSIGHT. 2021;6(6):141462.

Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis
Reich M, Spomer L, Klindt C, Fuchs K, Stindt J, Deutschmann K, Höhne J, Liaskou E, Hov J, Karlsen T, Beuers U, Verheij J, Ferreira-Gonzalez S, Hirschfield G, Forbes S, Schramm C, Esposito I, Nierhoff D, Fickert P, Fuchs C, Trauner M, García-Beccaria M, Gabernet G, Nahnsen S, Mallm J, Vogel M, Schoonjans K, Lautwein T, Köhrer K, Häussinger D, Luedde T, Heikenwalder M, Keitel V
J HEPATOL. 2021;75(3):634-646.

Drug-induced liver injury at a tertiary care centre in Germany: Model for End-stage Liver Disease is the best predictor of outcome
Reike-Kunze M, Zenouzi R, Hartl J, Krech T, Weidemann S, Sterneck M, Weiler-Normann C, Lohse A, Schramm C, Sebode M
LIVER INT. 2021;41(10):2383-2395.

Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER‬‬‬
Rüther D, Sebode M, Lohse A, Wernicke S, Böttinger E, Casar C, Braun F, Schramm C
CLIN RES HEPATOL GAS. 2021;45(6):.

Bone microarchitecture in patients with autoimmune hepatitis
Schmidt C, Stürznickel J, Strahl A, Oheim R, Weiler-Normann C, Sebode M, Barvencik F, Lohse A, Schinke T, Amling M, Schramm C, Rolvien T
J BONE MINER RES. 2021;36(7):1316-1325.

Europäisches Referenznetzwerk für seltene Lebererkrankungen (ERN RARE-LIVER)
Schulz L, Sebode M, Schramm C, Lohse A
INTERNIST. 2021;62(4):441-448.

Cell-autonomous hepatocyte-specific GP130 signaling is sufficient to trigger a robust innate immune response in mice
Schumacher N, Yan K, Gandraß M, Müller M, Krisp C, Häsler R, Carambia A, Nofer J, Bernardes J, Khouja M, Thomsen I, Chalupsky K, Bolik J, Hölscher C, Wunderlich T, Herkel J, Rosenstiel P, Schramm C, Schlüter H, Renné T, Mittrücker H, Rose-John S, Schmidt-Arras D
J HEPATOL. 2021;74(2):407-418.

Aryl Hydrocarbon Receptor Activity in Hepatocytes Sensitizes to Hyperacute Acetaminophen-Induced Hepatotoxicity in Mice
Schuran F, Lommetz C, Steudter A, Ghallab A, Wieschendorf B, Schwinge D, Zuehlke S, Reinders J, Heeren J, Lohse A, Schramm C, Herkel J, Carambia A
CELL MOL GASTROENTER. 2021;11(2):371-388.

Health-related quality of life in autoimmune hepatitis
Snijders R, Milkiewicz P, Schramm C, Gevers T
WORLD J HEPATOL. 2021;13(11):1642-1652.

Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis
Soret P, Lam L, Carrat F, Smets L, Berg T, Carbone M, Invernizzi P, Leroy V, Trivedi P, Cazzagon N, Weiler-Normann C, Alric L, Rosa-Hezode I, Heurgué A, Cervoni J, Dumortier J, Potier P, Roux O, Silvain C, Bureau C, Anty R, Larrey D, Levy C, Pares A, Schramm C, Nevens F, Chazouillères O, Corpechot C
ALIMENT PHARM THER. 2021;53(10):1138-1146.

IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression
Stein S, Henze L, Poch T, Carambia A, Krech T, Preti M, Schuran F, Reich M, Keitel V, Fiorotto R, Strazzabosco M, Fischer L, Li J, Müller L, Wagner J, Gagliani N, Herkel J, Schwinge D, Schramm C
J HEPATOL. 2021;74(4):919-930.

Present and future role of endoscopic retrograde cholangiography in primary sclerosing cholangitis
Waldthaler A, Schramm C, Bergquist A
EUR J MED GENET. 2021;64(6):104231.

Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis
Wunsch E, Norman G, Milkiewicz M, Krawczyk M, Bentow C, Shums Z, Mahler M, Lopens S, Reinhold D, Franke A, Schramm C, Roggenbuck D, Milkiewicz P
ALIMENT PHARM THER. 2021;53(2):302-313.

Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey
Zecher B, Buescher G, Willemse J, Walmsley M, Taylor A, Leburgue A, Schramm C, Lohse A, Sebode M
UNITED EUR GASTROENT. 2021;9(7):797-808.

Schwere sekundär sklerosierende Cholangitis als Manifestation einer sehr seltenen Grunderkrankung
Zecher B, Zenouzi R, Lang M, Karagiannis P, Clauditz T, Fischer L, Sterneck M, Schramm C, Lohse A, Sebode M
INTERNIST. 2021;62(12):1349-1353.

Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis
Corpechot C, Chazouillères O, Belnou P, Montano-Loza A, Mason A, Ebadi M, Eurich D, Chopra S, Jacob D, Schramm C, Sterneck M, Bruns T, Reuken P, Rauchfuss F, Roccarina D, Thorburn D, Gerussi A, Trivedi P, Hirschfield G, McDowell P, Nevens F, Boillot O, Bosch A, Giostra E, Conti F, Poupon R, Parés A, Reig A, Donato M, Malinverno F, Floreani A, Russo F, Cazzagon N, Verhelst X, Goet J, Harms M, van Buuren H, Hansen B, Carrat F, Dumortier J
J HEPATOL. 2020;73(3):559-565.

Long-term outcome in PSC patients receiving azathioprine: Does immunosuppression have a positive effect on survival?
Creutzfeldt A, Piecha F, Schattenberg J, Schramm C, Lohse A
J HEPATOL. 2020;73(5):1285-1287.

Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities
Goeppert B, Folseraas T, Roessler S, Kloor M, Volckmar A, Endris V, Buchhalter I, Stenzinger A, Grzyb K, Grimsrud M, Gornicka B, von Seth E, Reynolds G, Franke A, Gotthardt D, Mehrabi A, Cheung A, Verheij J, Arola J, Mäkisalo H, Eide T, Weidemann S, Cheville J, Mazza G, Hirschfield G, Ponsioen C, Bergquist A, Milkiewicz P, Lazaridis K, Schramm C, Manns M, Färkkilä M, Vogel A, Boberg K, Schirmacher P, Karlsen T
HEPATOLOGY. 2020;72(4):1253-1266.

Features and outcome of AIH patients without elevation of IgG
Hartl J, Miquel R, Zachou K, Wong G, Asghar A, Pape S, Sebode M, Peiseler M, Zenouzi R, Ehlken H, Krech T, Weiler-Normann C, Drenth J, Oo Y, Dalekos G, Heneghan M, Schramm C, Lohse A
JHEP REP. 2020;2(3):100094.

Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
Hedin C, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A, Gerussi A, Saffioti F, Thorburn D, Nilsson E, Larsson G, Moum B, van Munster K, Ponsioen C, Levy C, Nogueira N, Bowlus C, Gotlieb N, Shibolet O, Lynch K, Chapman R, Rupp C, Vesterhus M, Jørgensen K, Rorsman F, Schramm C, Sabino J, Vermeire S, Zago A, Cazzagon N, Marschall H, Ytting H, Ben Belkacem K, Chazouilleres O, Almer S, Bergquist A
CLIN GASTROENTEROL H. 2020;18(10):2295-2304.e2.

Long-term survival after liver transplantation for autoimmune hepatitis - results from the European Liver Transplant Registry
Heinemann M, Adam R, Berenguer M, Mirza D, Malek-Hosseini S, O'Grady J, Lodge P, Pratschke J, Boudjema K, Paul A, Zieniewicz K, Fronek J, Weiss K, Karam V, Duvoux C, Lohse A, Schramm C
LIVER TRANSPLANT. 2020;26(7):866-877.

The Effects of Androgens on T Cells: Clues to Female Predominance in Autoimmune Liver Diseases?
Henze L, Schwinge D, Schramm C
FRONT IMMUNOL. 2020;11:.

The Transcription Factor Promyelocytic Leukemia Zinc Finger Protein Is Associated With Expression of Liver-Homing Receptors on Human Blood CD56bright Natural Killer Cells
Hess L, Martrus G, Ziegler A, Langeneckert A, Salzberger W, Goebels H, Sagebiel A, Hagen S, Poch T, Ravichandran G, Koch M, Schramm C, Oldhafer K, Fischer L, Tiegs G, Richert L, Bunders M, Lunemann S, Altfeld M
HEPATOL COMMUN. 2020;4(3):409-424.

Diagnostik und Therapie unklarer Gallengangsstenosen
Krause J, Ehlken H, Schramm C
DEUT MED WOCHENSCHR. 2020;145(5):306-312.

Monocytes as potential mediators of pathogen-induced Th17 differentiation in patients with primary sclerosing cholangitis (PSC)
Kunzmann L, Schoknecht T, Poch T, Henze L, Stein S, Kriz M, Grewe I, Preti M, Hartl J, Pannicke N, Peiseler M, Sebode M, Zenouzi R, Horvatits T, Böttcher M, Petersen B, Weiler-Normann C, Hess L, Ahrenstorf A, Lunemann S, Martrus G, Fischer L, Li J, Carambia A, Kluwe J, Huber S, Lohse A, Franke A, Herkel J, Schramm C, Schwinge D
HEPATOLOGY. 2020;72(4):1310-1326.

Diagnosis and treatment of primary biliary cholangitis
Laschtowitz A, de Veer R, Van der Meer A, Schramm C
UNITED EUR GASTROENT. 2020;8(6):667-674.

A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis
Liwinski T, Casar C, Ruehlemann M, Bang C, Sebode M, Hohenester S, Denk G, Lieb W, Lohse A, Franke A, Schramm C
ALIMENT PHARM THER. 2020;51(12):1417-1428.

Editorial: gut microbiota profile in patients with autoimmune hepatitis-a clue for adjunctive probiotic therapy? Authors' reply
Liwinski T, Schramm C
ALIMENT PHARM THER. 2020;52(2):394-395.

Alterations of the bile microbiome in primary sclerosing cholangitis
Liwinski T, Zenouzi R, John C, Ehlken H, Rühlemann M, Bang C, Groth S, Lieb W, Kantowski M, Andersen N, Schachschal G, Karlsen T, Hov J, Rösch T, Lohse A, Heeren J, Franke A, Schramm C
GUT. 2020;69(4):665-672.

Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
Lynch K, Chapman R, Keshav S, Montano-Loza A, Mason A, Kremer A, Vetter M, de Krijger M, Ponsioen C, Trivedi P, Hirschfield G, Schramm C, Liu C, Bowlus C, Estes D, Pratt D, Hedin C, Bergquist A, de Vries A, Janneke van der Woude C, Yu L, Assis D, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall H, Daretti L, Marzioni M, Yimam K, Perin N, Floreani A, Beretta-Piccoli B, Rogers J, Levy C
CLIN GASTROENTEROL H. 2020;18(1):179-187.e6.

Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months
Pape S, Gevers T, Vrolijk J, van Hoek B, Bouma G, van Nieuwkerk C, Taubert R, Jaeckel E, Manns M, Papp M, Sipeki N, Stickel F, Efe C, Ozaslan E, Purnak T, Nevens F, Kessener D, Kahraman A, Wedemeyer H, Hartl J, Schramm C, Lohse A, Drenth J, Heneghan M
CLIN GASTROENTEROL H. 2020;18(7):1609-1617.e4.

High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation
Pape S, Gevers T, Vrolijk J, van Hoek B, Bouma G, van Nieuwkerk C, Taubert R, Jaeckel E, Manns M, Papp M, Sipeki N, Stickel F, Efe C, Ozaslan E, Purnak T, Nevens F, Kessener D, Kahraman A, Wedemeyer H, Hartl J, Schramm C, Lohse A, Heneghan M, Drenth J
LIVER INT. 2020;40(9):2164-2171.

Aneurysm of the ascending aorta and dilation of the pulmonary trunk in a patient with homocysteinemia
Rillig F, Weiler-Normann C, Herget T, Schramm C
VASA. 2020;49(2):151-152.

Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species
Rühlemann M, Solovjeva M, Zenouzi R, Liwinski T, Kummen M, Lieb W, Hov J, Schramm C, Franke A, Bang C
GUT. 2020;69(10):1890-1892.

A System to Determine Risk of Osteoporosis in Patients With Autoimmune Hepatitis
Schmidt T, Schmidt C, Strahl A, Mussawy H, Rolvien T, Jandl N, Casar C, Oheim R, Schinke T, Lohse A, Amling M, Schramm C, Barvencik F
CLIN GASTROENTEROL H. 2020;18(1):226-233.e3.

Concise Commentary: Why Cholangioscopy for Indeterminate Biliary Strictures in PSC Is Still Not Good Enough
Schramm C
DIGEST DIS SCI. 2020;65(5):1479-1480.

Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment
Sebode M, Kloppenburg A, Aigner A, Lohse A, Schramm C, Linder R
Z GASTROENTEROL. 2020;58(5):431-438.

Metamizole Has Been Overlooked as a Trigger for Acute Liver Injury and Acute Liver Failure
Sebode M, Lohse A, Schramm C
DTSCH ARZTEBL INT. 2020;117(37):610.

Metamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury
Sebode M, Reike-Kunze M, Weidemann S, Zenouzi R, Hartl J, Peiseler M, Liwinski T, Schulz L, Weiler-Normann C, Sterneck M, Lohse A, Schramm C
BRIT J CLIN PHARMACO. 2020;86(7):1406-1415.

Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis
Abdulkarim M, Zenouzi R, Sebode M, Schulz L, Quaas A, Lohse A, Schramm C, Weiler-Normann C
SCAND J GASTROENTERO. 2019;54(11):1391-1396.

Position statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER
Bernts L, Jones D, Kaatee M, Lohse A, Schramm C, Sturm E, Drenth J
ORPHANET J RARE DIS. 2019;14(1):169.

TNF-Producing Th1 Cells Are Selectively Expanded in Liver Infiltrates of Patients with Autoimmune Hepatitis
Bovensiepen C, Schakat M, Sebode M, Zenouzi R, Hartl J, Peiseler M, Li J, Henze L, Woestemeier A, Schramm C, Lohse A, Herkel J, Weiler-Normann C
J IMMUNOL. 2019;203(12):3148-3156.

Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis
Glaser F, John C, Engel B, Höh B, Weidemann S, Dieckhoff J, Stein S, Becker N, Casar C, Amrei Schuran F, Wieschendorf B, Preti M, Jessen F, Franke A, Carambia A, Lohse A, Ittrich H, Herkel J, Heeren J, Schramm C, Schwinge D
J HEPATOL. 2019;71(4):783-792.

Rate of Spleen Length Progression is a Marker of Outcome in Patients with Primary Sclerosing Cholangitis
Jung F, Cazzagon N, Vettorazzi E, Corpechot C, Chazouilleres O, Arrivé L, Lohse A, Schramm C, Ehlken H
CLIN GASTROENTEROL H. 2019;17(12):2613-2615.

Prospective comparison of diffusion-weighted MRI and dynamic Gd-EOB-DTPA-enhanced MRI for detection and staging of hepatic fibrosis in primary sclerosing cholangitis
Keller S, Sedlacik J, Schuler T, Buchert R, Avanesov M, Zenouzi R, Lohse A, Kooijman H, Fiehler J, Schramm C, Yamamura J
EUR RADIOL. 2019;29(2):818-828.

CCL21-expression and accumulation of CCR7 NK cells in livers of patients with primary sclerosing cholangitis
Langeneckert A, Lunemann S, Martrus G, Salzberger W, Hess L, Ziegler A, Poch T, Ravichandran G, Matschl U, Bosse J, Tiegs G, Fischer L, Koch M, Herkel J, Oldhafer K, Schramm C, Altfeld M
EUR J IMMUNOL. 2019;49(5):758-769.

Human liver-derived CXCR6+ NK cells are predominantly educated through NKG2A and show reduced cytokine production
Lunemann S, Langeneckert A, Martrus G, Hess L, Salzberger W, Ziegler A, Löbl S, Poch T, Ravichandran G, Sauter J, Schmidt A, Schramm C, Oldhafer K, Altfeld M, Körner C
J LEUKOCYTE BIOL. 2019;105(6):1331-1340.

CD49a Expression Identifies a Subset of Intrahepatic Macrophages in Humans
Martrus G, Goebels H, Langeneckert A, Kah J, Flomm F, Ziegler A, Niehrs A, Löbl S, Russu K, Hess L, Salzberger W, Poch T, Nashan B, Schramm C, Oldhafer K, Dandri M, Koch M, Lunemann S, Altfeld M
FRONT IMMUNOL. 2019;10:1247.

Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis
Pape S, Gevers T, Belias M, Mustafajev I, Vrolijk J, van Hoek B, Bouma G, van Nieuwkerk C, Hartl J, Schramm C, Lohse A, Taubert R, Jaeckel E, Manns M, Papp M, Stickel F, Heneghan M, Drenth J
CLIN GASTROENTEROL H. 2019;17(10):2068-2075.e2.

Clinical management of autoimmune hepatitis
Pape S, Schramm C, Gevers T
UNITED EUR GASTROENT. 2019;7(9):1156-1163.

Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice
Ravichandran G, Neumann K, Berkhout L, Weidemann S, Langeneckert A, Schwinge D, Poch T, Huber S, Schiller B, Hess L, Ziegler A, Oldhafer K, Barikbin R, Schramm C, Altfeld M, Tiegs G
J HEPATOL. 2019;71(4):773-782.

Recommendations on the Use of Magnetic Resonance Imaging for Collaborative Multicenter Studies in Primary Sclerosing Cholangitis
Ringe K, Grigoriadis A, Halibasic E, Wacker F, Manns M, Schramm C, Lenzen H
HEPATOLOGY. 2019;69(3):1358-1359.

Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis
Rühlemann M, Liwinski T, Heinsen F, Bang C, Zenouzi R, Kummen M, Thingholm L, Tempel M, Lieb W, Karlsen T, Lohse A, Hov J, Denk G, Lammert F, Krawczyk M, Schramm C, Franke A
ALIMENT PHARM THER. 2019;50(5):580-589.

Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis
Schmidt T, Schwinge D, Rolvien T, Jeschke A, Schmidt C, Neven M, Butscheidt S, Kriz M, Kunzmann L, Mussawy H, Hubert J, Hawellek T, Rüther W, Oheim R, Barvencik F, Lohse A, Schramm C, Schinke T, Amling M
J HEPATOL. 2019;70(5):941-953.

Autoimmune Hepatitis Beyond Steroids: Effective Trial Design and Attention to Quality of Life
Schramm C
Clin Liver Dis (Hoboken). 2019;14(1):33-36.

Sex-related factors in autoimmune liver diseases
Schwinge D, Schramm C
SEMIN IMMUNOPATHOL. 2019;41(2):165-175.

Inflammatory Phenotype of Intrahepatic Sulfatide-Reactive Type II NKT Cells in Humans With Autoimmune Hepatitis
Sebode M, Wigger J, Filpe P, Fischer L, Weidemann S, Krech T, Weiler-Normann C, Peiseler M, Hartl J, Tolosa E, Herkel J, Schramm C, Lohse A, Arrenberg P
FRONT IMMUNOL. 2019;10:1065.

Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group
Than N, Hodson J, Schmidt-Martin D, Taubert R, Wawman R, Botter M, Gautam N, Bock K, Jones R, Appanna G, Godkin A, Montano-Loza A, Lammert F, Schramm C, Manns M, Swain M, Burak K, Adams D, Hirschfield G, Oo Y
JHEP REP. 2019;1(6):437-445.

Depression and anxiety in patients with different rare chronic diseases: A cross-sectional study
Uhlenbusch N, Löwe B, Härter M, Schramm C, Weiler-Normann C, Depping M
PLOS ONE. 2019;14(2):e0211343.

The Translational Landscape of the Human Heart
van Heesch S, Witte F, Schneider-Lunitz V, Schulz J, Adami E, Faber A, Kirchner M, Maatz H, Blachut S, Sandmann C, Kanda M, Worth C, Schafer S, Calviello L, Merriott R, Patone G, Hummel O, Wyler E, Obermayer B, Mücke M, Lindberg E, Trnka F, Memczak S, Schilling M, Felkin L, Barton P, Quaife N, Vanezis K, Diecke S, Mukai M, Mah N, Oh S, Kurtz A, Schramm C, Schwinge D, Sebode M, Harakalova M, Asselbergs F, Vink A, de Weger R, Viswanathan S, Widjaja A, Gärtner-Rommel A, Milting H, Dos Remedios C, Knosalla C, Mertins P, Landthaler M, Vingron M, Linke W, Seidman J, Seidman C, Rajewsky N, Ohler U, Cook S, Hubner N
CELL. 2019;178(1):242-260.e29.

Magnetic Resonance Imaging in Primary Sclerosing Cholangitis-Current State and Future Directions
Zenouzi R, Welle C, Venkatesh S, Schramm C, Eaton J
SEMIN LIVER DIS. 2019;39(3):369-380.

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis
Alberts R, de Vries E, Goode E, Jiang X, Sampaziotis F, Rombouts K, Böttcher K, Folseraas T, Weismüller T, Mason A, Wang W, Alexander G, Alvaro D, Bergquist A, Björkström N, Beuers U, Björnsson E, Boberg K, Bowlus C, Bragazzi M, Carbone M, Chazouillères O, Cheung A, Dalekos G, Eaton J, Eksteen B, Ellinghaus D, Färkkilä M, Festen E, Floreani A, Franceschet I, Gotthardt D, Hirschfield G, Hoek B, Holm K, Hohenester S, Hov J, Imhann F, Invernizzi P, Juran B, Lenzen H, Lieb W, Liu J, Marschall H, Marzioni M, Melum E, Milkiewicz P, Müller T, Pares A, Rupp C, Rust C, Sandford R, Schramm C, Schreiber S, Schrumpf E, Silverberg M, Srivastava B, Sterneck M, Teufel A, Vallier L, Verheij J, Vila A, Vries B, Zachou K, Chapman R, Manns M, Pinzani M, Rushbrook S, Lazaridis K, Franke A, Anderson C, Karlsen T, Ponsioen C, Weersma R
GUT. 2018;67(8):1517-1524.

Corticosteroid Therapy Improves the Outcome of Autoimmune Hepatitis-Induced Acute Liver Failure
Anastasiou O, Dogan-Cavus B, Kucukoglu O, Baba H, Kahraman A, Gerken G, Schramm C, Canbay A
DIGESTION. 2018;98(2):104-111.

Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis
Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, von Felden J, Weiler-Normann C, Schramm C, Lohse A
J HEPATOL. 2018;68(4):754-763.

Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis.
Keller S, Aigner A, Zenouzi R, Kim A, Meijer A, Weidemann S, Krech T, Lohse A, Adam G, Schramm C, Yamamura J
PLOS ONE. 2018;13(3):e0193929.

Gadolinium-based relative contrast enhancement in primary sclerosing cholangitis: additional benefit for clinicians?
Keller S, Venkatesh S, Avanesov M, Weinrich J, Zenouzi R, Schramm C, Adam G, Yamamura J
CLIN RADIOL. 2018;73(7):677.e1-677.e6.

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
Kowdley K, Luketic V, Chapman R, Hirschfield G, Poupon R, Schramm C, Vincent C, Rust C, Parés A, Mason A, Marschall H, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, Böhm O, Pencek R, Jones D
HEPATOLOGY. 2018;67(5):1890-1902.

Primär sklerosierende Cholangitis: Aktuelle Diagnostik und Therapie
Liwinski T, Schramm C
INTERNIST. 2018;59(6):551-559.

Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture
Lunemann S, Schöbel A, Kah J, Fittje P, Hölzemer A, Langeneckert A, Hess L, Poch T, Martrus G, Garcia-Beltran W, Körner C, Ziegler A, Richert L, Oldhafer K, Schulze Zur Wiesch J, Schramm C, Dandri M, Herker E, Altfeld M
GASTROENTEROLOGY. 2018;155(5):1366-1371.

Colitis Promotes a Pathological Condition of the Liver in the Absence of Foxp3 Regulatory T Cells
Mathies F, Steffens N, Kleinschmidt D, Stuhlmann F, Huber F, Roy U, Meyer T, Luetgehetmann M, von Petersdorff M, Seiz O, Herkel J, Schramm C, Flavell R, Gagliani N, Krebs C, Panzer U, Abdullah Z, Strowig T, Bedke T, Huber S
J IMMUNOL. 2018;201(12):3558-3568.

HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage
Muscate F, Stetter N, Schramm C, Schulze Zur Wiesch J, Bosurgi L, Jacobs T
FRONT IMMUNOL. 2018;9:2611.

Efficacy and Limitations of Budesonide as a Second-line Treatment for Patients With Autoimmune Hepatitis
Peiseler M, Liebscher T, Sebode M, Zenouzi R, Hartl J, Ehlken H, Pannicke N, Weiler-Normann C, Lohse A, Schramm C
CLIN GASTROENTEROL H. 2018;16(2):260-267.e1.

Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis
Peiseler M, Reiners D, Pinnschmidt H, Sebode M, Jung F, Hartl J, Zenouzi R, Ehlken H, Groth S, Schachschal G, Rösch T, Weiler-Normann C, Lohse A, Schramm C
PLOS ONE. 2018;13(8):.

Immunosuppression as effective therapy for eosinophilic cholangiopathy: A case series and review of the literature
Reher D, Schramm C, Brinkert F, Weidemann S, Plauth M, Lohse A, Weiler-Normann C
GastroHep. 2018;1(1):33-44.

Immunosuppression as efficient therapy for Eosinophilic Cholangitis: A case series and review of the literature
Reher D, Schramm C, Brinkert F, Weidemann S, Plauth M, Lohse A, Weiler-Normann C
2018. Zeitschrift für Gastroenterologie. 01. Aufl. Georg Thieme Verlag KG, E2-E89.

Tissue-resident NK cells differ in their expression profile of the nutrient transporters Glut1, CD98 and CD71
Salzberger W, Martrus G, Bachmann K, Goebels H, Heß L, Koch M, Langeneckert A, Lunemann S, Oldhafer K, Pfeifer C, Poch T, Richert L, Schramm C, Wahib R, Bunders M, Altfeld M
PLOS ONE. 2018;13(7):e0201170.

Disease duration and stage influence bone microstructure in patients with primary biliary cholangitis
Schmidt T, Schmidt C, Schmidt F, Butscheidt S, Mussawy H, Hubert J, Hawellek T, Oehler N, Barvencik F, Lohse A, Schinke T, Schramm C, Amling M, Rolvien T
J BONE MINER RES. 2018;33(6):1011-1019.

Bile Acids, the Microbiome, Immunity, and Liver Tumors
Schramm C
NEW ENGL J MED. 2018;379(9):888-890.

Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance
Sebode M, Weiler-Normann C, Liwinski T, Schramm C
FRONT IMMUNOL. 2018;9:609.

Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype
Sowa M, Kolenda R, Baumgart D, Pratschke J, Papp M, Tornai T, Suchanski J, Bogdanos D, Mytilinaiou M, Hammermann J, Laass M, Conrad K, Schramm C, Franke A, Roggenbuck D, Schierack P
FRONT IMMUNOL. 2018;9:1959.

Acute hepatitis as a prequel to very severe aplastic anemia
Weiler-Normann C, Hartl J, Weidemann S, von Pein U, Fiedler W, Schramm C, Brinkert F, Kröger N, Christopeit M
Z GASTROENTEROL. 2018;56(1):51-54.

Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret
Zenouzi R, Liwinski T, Yamamura J, Weiler-Normann C, Sebode M, Keller S, Lohse A, Schramm C
ALIMENT PHARM THER. 2018;48(2):169-178.

Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure
Zenouzi R, von der Gablentz J, Heldmann M, Göttlich M, Weiler-Normann C, Sebode M, Ehlken H, Hartl J, Fellbrich A, Siemonsen S, Schramm C, Münte T, Lohse A
PLOS ONE. 2018;13(1):e0190005.

Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline

J HEPATOL. 2017;66(6):1265-1281.

Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline
Aabakken L, Karlsen T, Albert J, Arvanitakis M, Chazouilleres O, Dumonceau J, Färkkilä M, Fickert P, Hirschfield G, Laghi A, Marzioni M, Fernandez M, Pereira S, Pohl J, Poley J, Ponsioen C, Schramm C, Swahn F, Tringali A, Hassan C
ENDOSCOPY. 2017;49(6):588-608.

Metabolic Circuit Involving Free Fatty Acids, microRNA 122, and Triglyceride Synthesis in Liver and Muscle Tissues
Chai C, Rivkin M, Berkovits L, Simerzin A, Zorde-Khvalevsky E, Rosenberg N, Klein S, Yaish D, Durst R, Shpitzen S, Udi S, Tam J, Heeren J, Worthmann A, Schramm C, Kluwe J, Ravid R, Hornstein E, Giladi H, Galun E
GASTROENTEROLOGY. 2017;153(5):1404-1415.

Risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: diagnosis and surveillance
Ehlken H, Zenouzi R, Schramm C
CURR OPIN GASTROEN. 2017;33(2):78-84.

norUrsodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis
Fickert P, Hirschfield G, Denk G, Marschall H, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter F, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns M, Trauner M
J HEPATOL. 2017;67(3):549-558.

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease
Ji S, Juran B, Mucha S, Folseraas T, Jostins L, Melum E, Kumasaka N, Atkinson E, Schlicht E, Liu J, Shah T, Gutierrez-Achury J, Boberg K, Bergquist A, Vermeire S, Eksteen B, Durie P, Farkkila M, Müller T, Schramm C, Sterneck M, Weismüller T, Gotthardt D, Ellinghaus D, Braun F, Teufel A, Laudes M, Lieb W, Jacobs G, Beuers U, Weersma R, Wijmenga C, Marschall H, Milkiewicz P, Pares A, Kontula K, Chazouillères O, Invernizzi P, Goode E, Spiess K, Moore C, Sambrook J, Ouwehand W, Roberts D, Danesh J, Floreani A, Gulamhusein A, Eaton J, Schreiber S, Coltescu C, Bowlus C, Luketic V, Odin J, Chopra K, Kowdley K, Chalasani N, Manns M, Srivastava B, Mells G, Sandford R, Alexander G, Gaffney D, Chapman R, Hirschfield G, de Andrade M, Rushbrook S, Franke A, Karlsen T, Lazaridis K, Anderson C
NAT GENET. 2017;49(2):269-273.

Autoimmune hepatitis - update on clinical management in 2017
Liwinski T, Schramm C
CLIN RES HEPATOL GAS. 2017;41(6):617-625.

Proliferative capacity exhibited by human liver-resident CD49a+CD25+ NK cells
Martrus G, Kautz T, Lunemann S, Richert L, Glau L, Salzberger W, Goebels H, Langeneckert A, Hess L, Poch T, Schramm C, Oldhafer K, Koch M, Tolosa E, Nashan B, Altfeld M
PLOS ONE. 2017;12(8):e0182532.

Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis
Rühlemann M, Heinsen F, Zenouzi R, Lieb W, Franke A, Schramm C
GUT. 2017;66(4):753-754.

CD4+ T cells from patients with primary sclerosing cholangitis exhibit reduced apoptosis and down-regulation of proapoptotic Bim in peripheral blood
Schoknecht T, Schwinge D, Stein S, Weiler-Normann C, Sebode M, Mucha S, Otto B, Ellinghaus E, Stahl F, Franke A, Lohse A, Herkel J, Schramm C
J LEUKOCYTE BIOL. 2017;101(2):589-597.

Recommendations on the use of MRI in PSC-A position statement from the International PSC study group
Schramm C, Eaton J, Ringe K, Venkatesh S, Yamamura J
HEPATOLOGY. 2017;66(5):1675-1688.

Die erste deutschsprachige Leitlinie zu autoimmunen Lebererkrankungen
Schramm C, Strassburg C
DEUT MED WOCHENSCHR. 2017;142(24):1850-1854.

Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related with IL-12 signaling
Schwinge D, von Haxthausen F, Quaas A, Carambia A, Otto B, Glaser F, Höh B, Thiele N, Schoknecht T, Huber S, Steffens N, Lohse A, Herkel J, Schramm C
J HEPATOL. 2017;66(4):798-805.

Anti-TNF-α for necrotizing sarcoid granulomatosis of the liver
Sebode M, Weidemann S, Wehmeyer M, Lohse A, Schramm C
HEPATOLOGY. 2017;65(4):1410-1412.

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis
Weismüller T, Trivedi P, Bergquist A, Imam M, Lenzen H, Ponsioen C, Holm K, Gotthardt D, Färkkilä M, Marschall H, Thorburn D, Weersma R, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis K, Almer S, Pereira S, Levy C, Mason A, Naess S, Bowlus C, Floreani A, Halilbasic E, Yimam K, Milkiewicz P, Beuers U, Huynh D, Pares A, Manser C, Dalekos G, Eksteen B, Invernizzi P, Berg C, Kirchner G, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran B, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman R, Karlsen T, Schrumpf E, Strassburg C, Manns M, Lindor K, Hirschfield G, Hansen B, Boberg K
GASTROENTEROLOGY. 2017;152(8):1975-1984.e8.

Immunology of hepatic diseases during pregnancy
Bremer L, Schramm C, Tiegs G
SEMIN IMMUNOPATHOL. 2016;38(6):669-685.

Two Cases of Hepatosplenic T-Cell Lymphoma in Adolescents Treated for Autoimmune Hepatitis
Brinkert F, Arrenberg P, Krech T, Grabhorn E, Lohse A, Schramm C
PEDIATRICS. 2016;138(3):e20154245.

Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis
Ehlken H, Wroblewski R, Corpechot C, Arrivé L, Lezius S, Hartl J, Denzer U, Lohse A, Chazouilleres O, Schramm C
GUT. 2016;65(7):1230-1232.

Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis
Ehlken H, Wroblewski R, Corpechot C, Arrivé L, Rieger T, Hartl J, Lezius S, Hübener P, Schulze K, Zenouzi R, Sebode M, Peiseler M, Denzer U, Quaas A, Weiler-Normann C, Lohse A, Chazouilleres O, Schramm C
PLOS ONE. 2016;11(10):e0164224.

Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis
Hartl J, Denzer U, Ehlken H, Zenouzi R, Peiseler M, Sebode M, Hübener S, Pannicke N, Weiler-Normann C, Quaas A, Lohse A, Schramm C
J HEPATOL. 2016;65(4):769-75.

Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis - a retrospective multicenter analysis
Hildebrand T, Pannicke N, Dechene A, Gotthardt D, Kirchner G, Reiter F, Sterneck M, Herzer K, Lenzen H, Rupp C, Barg-Hock H, de Leuw P, Teufel A, Zimmer V, Lammert F, Sarrazin C, Spengler U, Rust C, Manns M, Strassburg C, Schramm C, Weismüller T
LIVER TRANSPLANT. 2016;22(1):42-52.

Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance
Hübener S, Oo Y, Than N, Hübener P, Weiler-Normann C, Lohse A, Schramm C
CLIN GASTROENTEROL H. 2016;14(3):445-453.

Reply to: Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance.
Hübener S, Than N, Oo Y, Lohse A, Schramm C
CLIN GASTROENTEROL H. 2016;14(7):1063-4.

Diffusion-weighted MRI for detection of hepatic osteodystrophy in primary sclerosing cholangitis a comparison study with dual-energy X-ray absorptiometry
Keller S, Ittrich H, Schramm C, Lohse A, Amling M, Adam G, Yamamura J
JPN J RADIOL. 2016;34(10):677-683.

Acute Ebola virus disease patient treatment and health-related quality of life in health care professionals: A controlled study
Lehmann M, Brünahl C, Addo M, Becker S, Schmiedel S, Lohse A, Schramm C, Löwe B
J PSYCHOSOM RES. 2016;83:69-74.

Inflammation-Induced Expression and Secretion of MicroRNA 122 Leads to Reduced Blood Levels of Kidney-derived Erythropoietin and Anemia
Rivkin M, Simerzin A, Zorde-Khvalevsky E, Chai C, Yuval J, Rosenberg N, Harari-Steinfeld R, Schneider R, Amir G, Condiotti R, Heikenwalder M, Weber A, Schramm C, Wege H, Kluwe J, Galun E, Giladi H
GASTROENTEROLOGY. 2016;151(5):999-1010.e3.

Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy
Than N, Wiegard C, Weiler-Normann C, Füssel K, Mann J, Hodson J, Hirschfield G, Lohse A, Adams D, Schramm C, Oo Y
SCAND J GASTROENTERO. 2016;51(3):329-336.

Opposing role of tumor necrosis factor receptor 1 signaling in T cell-mediated hepatitis and bacterial infection in mice
Wroblewski R, Armaka M, Kondylis V, Pasparakis M, Walczak H, Mittrücker H, Schramm C, Lohse A, Kollias G, Ehlken H
HEPATOLOGY. 2016;64(2):508-521.

No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis
Zenouzi R, Weismüller T, Jørgensen K, Bubenheim M, Lenzen H, Hübener P, Schulze K, Weiler-Normann C, Sebode M, Ehlken H, Pannicke N, Hartl J, Peiseler M, Hübener S, Karlsen T, Boberg K, Manns M, Lohse A, Schramm C
CLIN GASTROENTEROL H. 2016;14(12):1806-1812.

Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice
Carambia A, Freund B, Schwinge D, Bruns O, Salmen S, Ittrich H, Reimer R, Heine M, Huber S, Waurisch C, Eychmüller A, Wraith D, Korn T, Nielsen P, Weller H, Schramm C, Lüth S, Lohse A, Heeren J, Herkel J
J HEPATOL. 2015;62(6):1349-1356.

How Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed?
Ehlken H, Schramm C
VISZERALMEDIZIN. 2015;31(3):173-7.

Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis
Hartl J, Ehlken H, Weiler-Normann C, Sebode M, Kreuels B, Pannicke N, Zenouzi R, Glaubke C, Lohse A, Schramm C
J HEPATOL. 2015;62(3):642-6.

Litomosoides sigmodontis induces TGF-β receptor responsive, IL-10-producing T cells that suppress bystander T-cell proliferation in mice
Hartmann W, Schramm C, Breloer M
EUR J IMMUNOL. 2015;45(9):2568-81.

Der klinisch und wissenschaftlich tätige Arzt– aktueller Stand und Perspektiven
Huber S, Schramm C
Z GASTROENTEROL. 2015;53(2):137-8.

Acute and Chronic Inflammation of the Biliary System
Lankisch T, Bektas H, Dechêne A, Ehlken H, Kirchner G, Lang H, Schramm C
VISZERALMEDIZIN. 2015;31(3):200-3.

Ebola and psychological stress of health care professionals
Lehmann M, Brünahl C, Löwe B, Addo M, Schmiedel S, Lohse A, Schramm C
EMERG INFECT DIS. 2015;21(5):913-914.

Psychosoziale Belastungen von Ärzten und Pflegepersonal bei der Behandlung eines mit dem Ebola-Virus infizierten Patienten am Universitätsklinikum Hamburg Eppendorf im September 2014
Lehmann M, Brünahl C, Löwe B, Addo M, Schramm C, Schmiedel S, Lohse A
2015. Psycho - Somatik. .

S2k-Leitlinie nicht alkoholische Fettlebererkrankungen
Roeb E, Steffen H, Bantel H, Baumann U, Canbay A, Demir M, Drebber U, Geier A, Hampe J, Hellerbrand C, Pathil-Warth A, Schattenberg J, Schramm C, Seitz H, Stefan N, Tacke F, Tannapfel A, Lynen Jansen P, Bojunga J
Z GASTROENTEROL. 2015;53(7):668-723.

Primary Biliary Cirrhosis: Time to Replace a Misnomer: Reply to Giovanni Battista Levi Sandri
Schramm C, Wahl I, Lohse A
HEPATOLOGY. 2015;61(4):1435.

Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with PrimarCortico-Cerebellar Structural Connectivity Is Related to Residual Motor Output in Chronic Strokey Sclerosing Cholangitis
Schulze K, Weismüller T, Bubenheim M, Hübener P, Zenouzi R, Lenzen H, Rupp C, Gotthardt D, de Leuw P, Teufel A, Zimmer V, Reiter F, Rust C, Tharun L, Quaas A, Weidemann S, Lammert F, Sarrazin C, Manns M, Lohse A, Schramm C
PLOS ONE. 2015;10(10):Art. e0140525.

Testosterone Suppresses Hepatic Inflammation by the Downregulation of IL-17, CXCL-9, and CXCL-10 in a Mouse Model of Experimental Acute Cholangitis
Schwinge D, Carambia A, Quaas A, Krech T, Wegscheid C, Tiegs G, Prinz I, Lohse A, Herkel J, Schramm C
J IMMUNOL. 2015;194(6):2522-30.

Phenotypic alterations of regulatory T cells in autoimmune hepatitis: causal or associated with treatment and remission?
Sebode M, Peiseler M, Weiler-Normann C, Schramm C, Lohse A, Herkel J
HEPATOLOGY. 2015;61(2):736-737.

AIH:Which Alternative for Difficult-to-Treat Patients?
Sebode M, Schramm C
DIGEST DIS. 2015;33 Suppl 2:83-7.

Natural killer T cells: Novel players in biliary disease?
Sebode M, Schramm C
HEPATOLOGY. 2015;62(4):999-1000.

24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis
Sombetzki M, Fuchs C, Fickert P, Österreicher C, Mueller M, Claudel T, Loebermann M, Engelmann R, Langner C, Sahin E, Schwinge D, Günther N, Schramm C, Mueller-Hilke B, Reisinger E, Trauner M
J HEPATOL. 2015;62(4):871-8.

Primary biliary "cirrhosis" time to replace a misnomer
Wahl I, Feige A, Löwe B, Weiler-Normann C, Rose M, Lohse A, Schramm C
HEPATOLOGY. 2015;61(3):1091.

TGF-β-dependent induction of CD4⁺CD25⁺Foxp3⁺ Tregs by liver sinusoidal endothelial cells
Carambia A, Freund B, Schwinge D, Heine M, Laschtowitz A, Huber S, Wraith D, Korn T, Schramm C, Lohse A, Heeren J, Herkel J
J HEPATOL. 2014;61(3):594-9.

Genome-wide association study identifies variants associated with autoimmune hepatitis type 1
de Boer Y, van Gerven N, Zwiers A, Verwer B, van Hoek B, van Erpecum K, Beuers U, van Buuren H, Drenth J, den Ouden J, Verdonk R, Koek G, Brouwer J, Guichelaar M, Vrolijk J, Kraal G, Mulder C, van Nieuwkerk C, Fischer J, Berg T, Stickel F, Sarrazin C, Schramm C, Lohse A, Weiler-Normann C, Lerch M, Nauck M, Völzke H, Homuth G, Bloemena E, Verspaget H, Kumar V, Zhernakova A, Wijmenga C, Franke L, Bouma G
GASTROENTEROLOGY. 2014;147(2):443-452.

Transient elastography in primary sclerosing cholangitis-the value as a prognostic factor and limitations
Ehlken H, Lohse A, Schramm C
GASTROENTEROLOGY. 2014;147(2):542-543.

PSC: Novel disease associations providing pathogenetic clues?
Ehlken H, Schramm C
J HEPATOL. 2014;60(4):687-688.

Imaging of the murine biliopancreatic tract at 7 tesla: Technique and results in a model of primary sclerosing cholangitis
Ernst T, Schwinge D, Raabe N, Daubmann A, Kaul M, Adam G, Schramm C, Ittrich H
J MAGN RESON IMAGING. 2014;40(6):1355-1364.

Characterization of animal models for primary sclerosing cholangitis (PSC)
Fickert P, Pollheimer M, Beuers U, Lackner C, Hirschfield G, Housset C, Keitel V, Schramm C, Marschall H, Karlsen T, Melum E, Kaser A, Eksteen B, Strazzabosco M, Manns M, Trauner M
J HEPATOL. 2014;60(6):1290-1303.

An Unresectable Klatskin's Tumor?
Hartl J, Werner T, Schramm C
GASTROENTEROLOGY. 2014;146(7):e3-e4.

Autoimmune hepatitis on the rise
Schramm C, Lohse A
J HEPATOL. 2014;60(3):478-479.

Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis
Schramm C, Wahl I, Weiler-Normann C, Voigt K, Wiegard C, Glaubke C, Brähler E, Löwe B, Lohse A, Rose M
J HEPATOL. 2014;60(3):618-624.

Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms
Sebode M, Peiseler M, Franke B, Schwinge D, Schoknecht T, Wortmann F, Quaas A, Petersen B, Ellinghaus E, Baron U, Olek S, Wiegard C, Weiler-Normann C, Lohse A, Herkel J, Schramm C
J HEPATOL. 2014;60(5):1010-6.

Reply to: "Anti-TNF-induced autoimmune hepatitis"
Weiler-Normann C, Herkel J, Schramm C, Lohse A
J HEPATOL. 2014;61(1):170-171.

Low Risk of Hepatocellular Carcinoma in Patients With Primary Sclerosing Cholangitis With Cirrhosis
Zenouzi R, Weismüller T, Hübener P, Schulze K, Bubenheim M, Pannicke N, Weiler-Normann C, Lenzen H, Manns M, Lohse A, Schramm C
CLIN GASTROENTEROL H. 2014.

Inhibition of inflammatory CD4 T cell activity by murine liver sinusoidal endothelial cells
Carambia A, Frenzel C, Bruns O, Schwinge D, Reimer R, Hohenberg H, Huber S, Tiegs G, Schramm C, Lohse A, Herkel J
J HEPATOL. 2013;58(1):112-8.

Primary sclerosing cholangitis and cholangiocarcinoma: pathogenesis and modes of diagnostics
Ehlken H, Schramm C
DIGEST DIS. 2013;31(1):118-25.

Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4.
Ellinghaus D, Folseraas T, Holm K, Ellinghaus E, Melum E, Balschun T, Laerdahl J, Shiryaev A, Gotthardt D, Weismüller T, Schramm C, Wittig M, Bergquist A, Björnsson E, Marschall H, Vatn M, Teufel A, Rust C, Gieger C, Wichmann H, Runz H, Sterneck M, Rupp C, Braun F, Weersma R, Wijmenga C, Ponsioen C, Mathew C, Rutgeerts P, Vermeire S, Schrumpf E, Hov J, Manns M, Boberg K, Schreiber S, Franke A, Karlsen T
HEPATOLOGY. 2013;58(3):1074-1083.

Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis
Katt J, Schwinge D, Schoknecht T, Quaas A, Sobottka I, Burandt E, Becker C, Neurath M, Lohse A, Herkel J, Schramm C
HEPATOLOGY. 2013;58(3):1084-93.

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
Liu J, Hov J, Folseraas T, Ellinghaus E, Rushbrook S, Doncheva N, Andreassen O, Weersma R, Weismüller T, Eksteen B, Invernizzi P, Hirschfield G, Gotthardt D, Pares A, Ellinghaus D, Shah T, Juran B, Milkiewicz P, Rust C, Schramm C, Müller T, Srivastava B, Dalekos G, Nöthen M, Herms S, Winkelmann J, Mitrovic M, Braun F, Ponsioen C, Croucher P, Sterneck M, Teufel A, Mason A, Saarela J, Leppa V, Dorfman R, Alvaro D, Floreani A, Onengut-Gumuscu S, Rich S, Thompson W, Schork A, Næss S, Thomsen I, Mayr G, König I, Hveem K, Cleynen I, Gutierrez-Achury J, Ricaño-Ponce I, van Heel D, Björnsson E, Sandford R, Durie P, Melum E, Vatn M, Silverberg M, Duerr R, Padyukov L, Brand S, Sans M, Annese V, Achkar J, Boberg K, Marschall H, Chazouillères O, Bowlus C, Wijmenga C, Schrumpf E, Vermeire S, Albrecht M, Rioux J, Alexander G, Bergquist A, Cho J, Schreiber S, Manns M, Färkkilä M, Dale A, Chapman R, Lazaridis K, Franke A, Anderson C, Karlsen T
NAT GENET. 2013;45(6):670-5.

Infiltration of peritumoural but tumour-free parenchyma with IgG4-positive plasma cells in hilar cholangiocarcinoma and pancreatic adenocarcinoma
Resheq Y, Quaas A, von Renteln D, Schramm C, Lohse A, Lüth S
DIGEST LIVER DIS. 2013;45(10):859-65.

Inflammatorische Erkrankungen mit Leber- und Gelenkbeteiligung. Eine differenzialdiagnostische Herausforderung
Sebode M, Schramm C, Lohse A
INTERNIST. 2013;54(4):441-448.

Some unusual cystic lesions of the liver
Wehmeyer M, Lohse A, Schramm C
GASTROENTEROLOGY. 2013;145(6):e1-2.

Reply to: "Use of TNFα antagonists in refractory AIH: revealing the unforeseen"
Weiler-Normann C, Schramm C, Lohse A
J HEPATOL. 2013;59(1):198-9.

Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis.
Weiler-Normann C, Schramm C, Quaas A, Wiegard C, Glaubke C, Pannicke N, Hübener S, Lohse A
J HEPATOL. 2013;58(3):529-534.

Induction of heme oxygenase 1 prevents progression of liver fibrosis in Mdr2 knockout mice
Barikbin R, Neureiter D, Wirth J, Erhardt A, Schwinge D, Kluwe J, Schramm C, Tiegs G, Sass G
HEPATOLOGY. 2012;55(2):553-562.

Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci.
Folseraas T, Melum E, Rausch P, Juran B, Ellinghaus E, Shiryaev A, Laerdahl J, Ellinghaus D, Schramm C, Weismüller T, Gotthardt D, Hov J, Clausen O, Weersma R, Janse M, Boberg K, Björnsson E, Marschall H, Cleynen I, Rosenstiel P, Holm K, Teufel A, Rust C, Gieger C, Wichmann H, Bergquist A, Ryu E, Ponsioen C, Runz H, Sterneck M, Vermeire S, Beuers U, Wijmenga C, Schrumpf E, Manns M, Lazaridis K, Schreiber S, Baines J, Franke A, Karlsen T
J HEPATOL. 2012;57(2):366-375.

Acute liver failure following minocycline treatment - a case report and review of the literature.
Kuhn A, Weiler-Normann C, Schramm C, Kluge S, Behne M, Lohse A, Benten D
Z GASTROENTEROL. 2012;50(8):771-775.

[Autoimmune liver diseases].
Pannicke N, Schramm C, Lohse A
INTERNIST. 2012;53(8):943-946.

Autoimmunerkrankungen der Leber
Pannicke N, Schramm C, Lohse A
INTERNIST. 2012;53(8):943-54; quiz 955-6.

Elevated γ-glutamyltransferase
Pannicke N, Werner T, Schramm C
GASTROENTEROLOGY. 2012;143(4):7-8.

FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency
Peiseler M, Sebode M, Franke B, Wortmann F, Schwinge D, Quaas A, Baron U, Olek S, Wiegard C, Lohse A, Weiler-Normann C, Schramm C, Herkel J
J HEPATOL. 2012;57(1):125-132.

An unusual cause of hypertriglyceridemic acute pancreatitis.
Resheq Y, Rinninger F, Lohse A, Schramm C
AM J GASTROENTEROL. 2012;107(6):957-959.

Gallbladder polyps in primary sclerosing cholangitis: indication for early intervention.
Schramm C, Lohse A
HEPATOLOGY. 2012;56(1):396.

Role of activin A in the induction of Foxp3+ and Foxp3- CD4+ regulatory T cells.
Huber S, Schramm C
CRIT REV IMMUNOL. 2011;31(1):53-60.

Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9.
Janse M, Lamberts L, Franke L, Raychaudhuri S, Ellinghaus E, Kirsten M, Melum E, Folseraas T, Schrumpf E, Bergquist A, Björnsson E, Fu J, Harm J, Groen H, Fehrmann R, Smolonska J, Berg v, Leonard H, Ophoff R, Porte R, Weismüller T, Schramm C, Sterneck M, Sterneck M, Günther R, Braun F, Vermeire S, Henckaerts L, Wijmenga C, Ponsioen C, Schreiber S, Karlsen T, Franke A, Weersma R
HEPATOLOGY. 2011;53(6):1977-1985.

Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci.
Melum E, Franke A, Schramm C, Weismüller T, Gotthardt D, Offner F, Juran B, Laerdahl J, Labi V, Björnsson E, Weersma R, Henckaerts L, Teufel A, Rust C, Ellinghaus E, Balschun T, Boberg K, Ellinghaus D, Bergquist A, Sauer P, Ryu E, Hov J, Wedemeyer J, Lindkvist B, Wittig M, Porte R, Holm K, Gieger C, Wichmann H, Stokkers P, Ponsioen C, Runz H, Stiehl A, Wijmenga C, Sterneck M, Vermeire S, Beuers U, Villunger A, Schrumpf E, Lazaridis K, Manns M, Schreiber S, Karlsen T
NAT GENET. 2011;43(1):17-19.

Primär sklerosierende Cholangitis - Herausforderungen gemeinsam meistern. Die Deutsche PSC-Studiengruppe
Schramm C, Gotthardt D, Spengler U, Schirmacher P, Weismüller T
Z GASTROENTEROL. 2011;49(1):63-65.

[Primary sclerosing cholangitis - challenges for all. The German Study Group PSC].
Schramm C, Gotthardt D, Spengler U, Schirmacher P, Weismüller T
Z GASTROENTEROL. 2011;49(1):63-65.

Role of mycophenolate mofetil in the treatment of autoimmune hepatitis.
Schramm C, Lohse A
J HEPATOL. 2011;55(3):510-511.

Drug induced liver injury and its relationship to autoimmune hepatitis.
Weiler-Normann C, Schramm C
J HEPATOL. 2011;55(4):747-749.

Pregnancy in primary sclerosing cholangitis.
Wellge B, Sterneck M, Teufel A, Rust C, Franke A, Schreiber S, Berg T, Günther R, Kreisel W, Zu Eulenburg C, Braun F, Beuers U, Galle P, Lohse A, Schramm C
GUT. 2011;60(8):1117-1121.

Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis.
Hov J, Keitel V, Laerdahl J, Spomer L, Ellinghaus E, ElSharawy A, Melum E, Boberg K, Manke T, Balschun T, Schramm C, Bergquist A, Weismüller T, Gotthardt D, Rust C, Henckaerts L, Onnie C, Weersma R, Sterneck M, Teufel A, Runz H, Stiehl A, Ponsioen C, Wijmenga C, Vatn M, Stokkers P, Vermeire S, Mathew C, Lie B, Beuers U, Manns M, Schreiber S, Schrumpf E, Häussinger D, Franke A, Karlsen T
PLOS ONE. 2010;5(8):12403.

Genome-wide association analysis in primary sclerosing cholangitis
Karlsen T, Franke A, Melum E, Kaser A, Hov J, Balschun T, Lie B, Bergquist A, Schramm C, Weismüller T, Gotthardt D, Rust C, Philipp E, Fritz T, Henckaerts L, Weersma R, Stokkers P, Ponsioen C, Wijmenga C, Sterneck M, Nothnagel M, Hampe J, Teufel A, Runz H, Rosenstiel P, Stiehl A, Vermeire S, Beuers U, Manns M, Schrumpf E, Boberg K, Schreiber S
GASTROENTEROLOGY. 2010;138(3):1102-1111.

[A rare cause of variceal bleeding].
Naderi J, Lohse A, Galle P, Schramm C
Z GASTROENTEROL. 2010;48(10):1215-1218.

Seltene Ursache einer Fundusvarizenblutung
Naderi J, Lohse A, Galle P, Schramm C
Z GASTROENTEROL. 2010;48(10):1215-8.

Primary liver transplantation for autoimmune Hepatitis: A comparative analysis of the European Liver Transplant Registry
Schramm C, Bubenheim M, Adam R, Karam V, Buckels J, O'Grady J, Jamieson N, Pollard S, Neuhaus P, Manns M, Porte R, Castaing D, Paul A, Traynor O, Garden J, Friman S, Ericzon B, Fischer L, Vitko S, Krawczyk M, Metselaar H, Foss A, Kilic M, Rolles K, Burra P, Rogiers X, Lohse A
LIVER TRANSPLANT. 2010;16(4):461-469.

Treatment response in patients with autoimmune hepatitis.
Schramm C, Weiler-Normann C, Wiegard C, Hellweg S, Müller S, Lohse A
HEPATOLOGY. 2010;52(6):2247-2248.

Activin a promotes the TGF-beta-induced conversion of CD4+CD25- T cells into Foxp3+ induced regulatory T cells.
Huber S, Stahl F, Schrader J, Lüth S, Presser K, Carambia A, Flavell R, Werner S, Blessing M, Herkel J, Schramm C
J IMMUNOL. 2009;182(8):4633-4640.

Autoimmune hepatic diseases: Prognosis and management of autoimmune hepatitis
Lohse A, Lüth S, Schramm C
2009. Autoimmune Hepatic Diseases. Permanyer Publications: 115-122.

Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome
Lüth S, Kanzler S, Frenzel C, Kasper H, Dienes H, Schramm C, Galle P, Herkel J, Lohse A
J CLIN GASTROENTEROL. 2009;43(1):75-80.

[Autoimmune liver diseases]
Lüth S, Weiler-Normann C, Schramm C, Lohse A
INTERNIST. 2009;50(3):310-317.

Autoimmunerkrankungen der Leber
Lüth S, Weiler-Normann C, Schramm C, Lohse A
INTERNIST. 2009;50(3):310-7.

A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade.
Weiler-Normann C, Wiegard C, Schramm C, Lohse A
AM J GASTROENTEROL. 2009;104(11):2877-2878.

Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future.
Wiegard C, Schramm C, Lohse A
SEMIN LIVER DIS. 2009;29(3):254-261.

Mycophenolate mofetil as second line therapy in autoimmune hepatitis?
Hennes E, Oo Y, Schramm C, Denzer U, Buggisch P, Wiegard C, Kanzler S, Schuchmann M, Boecher W, Galle P, Adams D, Lohse A
AM J GASTROENTEROL. 2008;103(12):3063-3070.

Simplified criteria for the diagnosis of autoimmune hepatitis.
Hennes E, Zeniya M, Czaja A, Parés A, Dalekos G, Krawitt E, Bittencourt P, Porta G, Boberg K, Hofer H, Bianchi F, Shibata M, Schramm C, Barbara E, Galle P, McFarlane I, Dienes H, Lohse A
HEPATOLOGY. 2008;48(1):169-176.

P38 MAP kinase signaling is required for the conversion of CD4+CD25- T cells into iTreg.
Huber S, Schrader J, Fritz G, Presser K, Schmitt S, Waisman A, Lüth S, Blessing M, Herkel J, Schramm C
PLOS ONE. 2008;3(10):3302.

Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis.
Lüth S, Herkel J, Kanzler S, Frenzel C, Galle P, Dienes H, Schramm C, Lohse A
J CLIN GASTROENTEROL. 2008;42(8):926-930.

Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs
Lüth S, Huber S, Schramm C, Buch T, Zander S, Stadelmann C, Brück W, Wraith D, Herkel J, Lohse A
J CLIN INVEST. 2008;118(10):3403-3410.

Coexpression of TGF-beta1 and IL-10 enables regulatory T cells to completely suppress airway hyperreactivity
Presser K, Schwinge D, Wegmann M, Huber S, Schmitt S, Quaas A, Maxeiner J, Finotto S, Lohse A, Blessing M, Schramm C
J IMMUNOL. 2008;181(11):7751-7758.

Adalimumab Could Suppress the Activity of Non Alcoholic Steatohepatitis (NASH).
Schramm C, Schneider A, Marx A, Lohse A
Z GASTROENTEROL. 2008;46(12):1369-1371.

Sorafenib-induced liver failure.
Schramm C, Schuch G, Lohse A
AM J GASTROENTEROL. 2008;103(8):2162-2163.

Unmasking autoimmune hepatitis under immunomodulatory treatment of multiple sclerosis--not only beta interferon.
Von Kalckreuth V, Lohse A, Schramm C
AM J GASTROENTEROL. 2008;103(8):2147-2148.

Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis.
Frenzel C, Herkel J, Lüth S, Galle P, Schramm C, Lohse A
AM J GASTROENTEROL. 2006;101(12):2731-2736.

TGF-beta and CD4+CD25+ regulatory T cells
Huber S, Schramm C
FRONT BIOSCI-LANDMRK. 2006;11(1):1014-1023.

Multiplex neuritis in a patient with autoimmune hepatitis: a case report
Luth S, Birklein F, Schramm C, Herkel J, Hennes E, Muller-Forell W, Galle P, Lohse A
WORLD J GASTROENTERO. 2006;12(33):5396-8.

Pregnancy in autoimmune hepatitisoutcome and risk factors
Schramm C, Herkel J, Beuers U, Kanzler S, Galle P, Lohse A
AM J GASTROENTEROL. 2006;101(3):556-60.

Die primär sklerosierende Cholangitis als Präkanzerose
Schramm C, Galle P
Z GASTROENTEROL. 2005;43(6):607-11.

Overlap syndromes of cholestatic liver diseases and auto-immune hepatitis.
Schramm C, Lohse A
CLIN REV ALLERG IMMU. 2005;28(2):105-14.

Autoimmune Lebererkrankungen: Diagnostik und Therapie
Bayer E, Schramm C, Kanzler S, Lohse A
Z GASTROENTEROL. 2004;42(1):19-30.

TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling
Becker C, Fantini M, Schramm C, Lehr H, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle P, Blessing M, Rose-John S, Neurath M
IMMUNITY. 2004;21(4):491-501.

Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells
Huber S, Schramm C, Lehr H, Mann A, Schmitt S, Becker C, Protschka M, Galle P, Neurath M, Blessing M
J IMMUNOL. 2004;173(11):6526-31.

TGFbeta regulates the CD4+CD25+ T-cell pool and the expression of Foxp3 in vivo
Schramm C, Huber S, Protschka M, Czochra P, Burg J, Schmitt E, Lohse A, Galle P, Blessing M
INT IMMUNOL. 2004;16(9):1241-1249.

Susceptibility to collagen-induced arthritis is modulated by TGFbeta responsiveness of T cells
Schramm C, Kriegsmann J, Protschka M, Huber S, Hansen T, Schmitt E, Galle P, Blessing M
ARTHRITIS RES THER. 2004;6(2):R114-R119.

Letzte Aktualisierung aus dem FIS: 20.12.2024 - 23:36 Uhr